Skip to content Skip to navigation
University of Warwick
  • Study
  • |
  • Research
  • |
  • Business
  • |
  • Alumni
  • |
  • News
  • |
  • About

University of Warwick
Publications service & WRAP

Highlight your research

  • WRAP
    • Home
    • Search WRAP
    • Browse by Warwick Author
    • Browse WRAP by Year
    • Browse WRAP by Subject
    • Browse WRAP by Department
    • Browse WRAP by Funder
    • Browse Theses by Department
  • Publications Service
    • Home
    • Search Publications Service
    • Browse by Warwick Author
    • Browse Publications service by Year
    • Browse Publications service by Subject
    • Browse Publications service by Department
    • Browse Publications service by Funder
  • Statistics
  • Help & Advice
University of Warwick

The Library

  • Login

New strategies for control of respiratory syncytial virus infection

Tools
- Tools
+ Tools

Nokes, D. James and Cane, Patricia (2008) New strategies for control of respiratory syncytial virus infection. Current Opinion in Infectious Diseases, Vol.21 (No.6). pp. 639-643. ISSN 0951-7375

Full text not available from this repository.
Official URL: http://dx.doi.org/10.1097/QCO.0b013e3283184245

Abstract

Purpose of review: To report on recent progress on the development and implementation of a vaccine against respiratory syncytial virus (RSV), on investigations of the mechanism of action of prophylactic antibodies and the potential for increased efficacy of those antibodies, and on candidate antiviral drugs against RSV. Recent findings: Follow-up data from RSV live attenuated vaccine trials in naive infants and young children strengthen the view that live attenuated vaccines will not predispose to exacerbated pneumonia upon natural infection. Data on the age distribution of RSV disease from the developing country setting highlight a need to investigate the effectiveness of live attenuated vaccination outside the 0-2 month age group. It has recently been shown that palivizumab, the only approved monoclonal antibody for prophylaxis of RSV, and which is used mainly in infants at high risk of severe RSV disease, allows abortive replication of the virus in the lungs of cotton rats. It has also been reported that a variant of palivizumab, motavizumab, has greater affinity for RSV and is now being investigated in clinical trials. Progress has been made on the development of antiviral compounds including RSV604, a novel benzodiazepine, and ALN-RSV01, based on a small interfering RNA, Summary: Advances in the treatment of RSV are more evident than in prevention. Obstacles to prevention of paediatric RSV disease may require new approaches to vaccine delivery.

Item Type: Journal Item
Subjects: Q Science > QR Microbiology > QR355 Virology
R Medicine > RC Internal medicine
R Medicine > RM Therapeutics. Pharmacology
Divisions: Faculty of Science > Life Sciences (2010- )
Library of Congress Subject Headings (LCSH): Respiratory syncytial virus -- Prevention, Antiviral agents, Vaccines, Respiratory organs -- Diseases -- Prevention
Journal or Publication Title: Current Opinion in Infectious Diseases
Publisher: Lippincott Williams & Wilkins
ISSN: 0951-7375
Date: December 2008
Volume: Vol.21
Number: No.6
Number of Pages: 5
Page Range: pp. 639-643
Identification Number: 10.1097/QCO.0b013e3283184245
Status: Peer Reviewed
Publication Status: Published
Access rights to Published version: Restricted or Subscription Access
Funder: Wellcome Trust (London, England)
URI: http://wrap.warwick.ac.uk/id/eprint/28932

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item View Item
twitter

Email us: publications@warwick.ac.uk
Contact Details
About Us